Meet an IBDIQ contributor /

Meena Bewtra, MD, PhD, MPH

About Meena Bewtra, MD, PhD, MPH

Meenakshi Bewtra, MD, PhD, MPH, is an associate professor of medicine and epidemiology at the University of Pennsylvania Perelman School of Medicine and a senior scholar in the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania. Dr. Bewtra sees patients with inflammatory bowel disease (IBD) at the Perelman Center for Advanced Medicine. Dr. Bewtra has been conducting clinical research for over 20 years in IBD with a focus on the natural history of IBD; outcomes of disease and medication safety using observational data and statistical modeling; measures of risk and risk tolerance for therapies using discrete choice experiment; and clinical trials for educational interventions and novel therapies. Dr. Bewtra is also the PI of the IBD-Immunology Initiative (I3), a prospective clinical and tissue biobank actively enrolling all inflammatory bowel disease patients seen at the University of Pennsylvania. The I3 has collaborators within the University of Pennsylvania, nationally and internationally in academia, private foundations, and industry, and is participating in several studies examining the basic mechanisms of IBD and predictors of response to therapies with the goal of improving personalized medicine in inflammatory bowel disease. Dr. Bewtra’s work has been funded by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Crohn’s & Colitis Foundation, the American Gastroenterological Association (AGA), the Patient-Centered Outcomes Research Institute (PCORI), pharmaceutical industries, and private philanthropy. She is currently a member of the Crohn’s & Colitis Foundation, the American Gastroenterology Association, the American College of Gastroenterology, and a founding member of the International Academy of Health Preference Research. Dr. Bewtra has served on the National Board for the Crohn’s & Colitis Foundation and is currently on the Executive Board of Doctors for America.


  • Research Funding: Takeda, Pfizer, Iterative Scopes, GSK
  • Consultant: Takeda, Pfizer, AbbVie, BMS, Imedex, MedEd Consultants, Janssen